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ABSTRACT
Objective: To determine if Lactobacillus reuteri is an effective treatment for infantile colic by reviewing
existing literature and performing a systematic analysis. Design: Systematic literature review.
Methods: The PubMed database was searched using the terms “Lactobacillus reuteri” and “colic.” The
yielded results were refined to only include human clinical trials published within the past 10 years.
Results: Chau et al., Savino et al., and Szajewska et al. each found that the average crying times were
significantly shorter for the L. reuteri group than they were for the probiotic group on days 7, 14, and 21.
All three trials also found that the L. reuteri group had a significantly higher number of infants who had ≥
50% reduction in their crying times by the end of the study.
Conclusion: The studies included in this review consistently showed therapeutic benefit in administering
L. reuteri to colicky breastfed infants. The subjects receiving L. reuteri had significant reductions in crying
times when compared to those who received placebo. These findings support the use of L. reuteri in the
management of infantile colic. However, these trials were slightly limited by their relatively small sample
sizes and further studies with larger sample sizes are necessary in order to assess the strength of this
conclusion.
INTRODUCTION
Infantile colic (IC) is generally known as excessive crying with an unknown cause. A more
structured definition is outlined by “the rule of three”: more than 3 hours of crying per day, over 3 days per
week, for over 3 weeks, in an otherwise healthy, well-fed infant.1 IC is fairly common, affecting as many
as 1 in 4 newborns which equates to approximately 1.2 million infants in the United States.2 It typically
begins in the first 2 weeks of life and usually goes away without intervention by 3 or 4 months of age.
While this is not a particularly long affliction, it has significant impacts on the infant, the parents, and even
clinicians, who often have no concrete explanations or solutions for their distressed patient.3,4
Having a colicky infant causes parental stress, and studies have shown that parental stress
contributes to colic, thus creating a vicious cycle. This makes infantile colic difficult to combat, and while it
usually subsides by 4 months, the degree of suffering the family experiences through this period is quite
significant. Studies have found colic to be associated with maternal depression, shaken baby syndrome,
and early cessation of breastfeeding.5 In order to prevent these possible ramifications of colic, there
needs to be an understanding of its cause, but unfortunately the pathophysiology behind colic has long
been elusive.
An underlying organic cause for colic is found in less than 5 percent of these infants and its
pathogenesis remains unclear.4 However, over the past 2 decades there has been increasing evidence
that gut microbiota is intimately tied to health and disease, and promise has been found in exploring the
connection between gut microbiota and IC. When compared to non-colicky infants, the gut microbiota of
infants with colic have less bacterial diversity and lower concentrations of protective, anti-inflammatory
bacteria, such as lactobacilli.6 Studies have revealed correlation of intestinal dysbiosis with IC, which
seems to stem from the chronic inflammatory response brought on by lack of microbiota diversity and
high populations of pathogenic bacteria in the gut.2,7
Due to the suspected involvement of gut microbiota on the pathophysiology behind colic, and the
protective effects of bacteria, such as lactobacilli, there have been numerous randomized controlled trials
(RCTs) evaluating the usefulness of probiotics in the treatment of IC. While their findings have been
mixed, evidence suggests that certain strains of probiotics, specifically Lactobacillus reuteri, can lead to
the resolution of infant colic. The development of a safe treatment would drastically decrease numerous
pediatric visits, parental burden, and potential long-term consequences for the infant. Therefore, it needs
to be determined if Lactobacillus reuteri is truly a solution to this problem.
PICO
Population: breastfed infants less than 6 months old who have been diagnosed with colic

Intervention: Lactobacillus reuteri
Comparison: placebo
Outcome: reduction in crying time

Screening

Identification

CLINICAL QUESTION
Is Lactobacillus reuteri more effective than placebo in reducing crying time in breastfed infants with colic?
Records identified through PubMed
with search terms “Lactobacillus
reuteri” AND “colic” and limited to
“Clinical Trials” and “Human
Species”
(n = 17)

Records after duplicates removed
(n = 17)
-

Eligibility

Records screened
(n = 17)

-

Full-text articles assessed
for eligibility
(n = 8)
Studies included in
qualitative synthesis
(n = 3)

-

Included

-

1.
2.
3.

Records excluded
(n = 9)
1 due to comparison with simethicone
3 because L. reuteri combined with another
probiotic
1 because study was focused on gut microbiota
2 because it was a different strain of Lactobacillus
1 because feces sample was their observed
outcome
1 because it was focused on safety of L. reuteri vs.
efficacy

Full-text articles excluded, with reasons
(n = 5)
1 only single blinded and didn't specify oil
ingredients
1 did not specifically look at decrease in crying time
1 because it was prophylactic instead of
preventative
2 studies used maltodextrin in oil

Studies included in quantitative synthesis (meta-analysis)
(n = 3)
Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, PlaceboControlled Trial by Savino, F., Cordisco, L., Tarasco, V, et al.
Probiotics for Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial
Investigating Lactobacillus reuteri DSM 17938 by Chau, K., Lau, E., Greenberg, S., et al.
Lactobacillus reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A
Randomized, Double-Blind, Placebo-Controlled Trial by Szajewska, H., Gyrczuk, E, & Horvath,
A.

Figure 1. PRISMA Flow Diagram depicting process of study selection

METHODS
A PubMed search was completed in September 2019 using the terms “Lactobacillus reuteri” AND
“colic”. Results were filtered to only include clinical trials involving the human species that were published
in the last 10 years. This yielded 17 articles. Upon evaluation of the studies, several did not meet the
predetermined inclusion and exclusion criteria seen in Table 1. Subsequent studies were ruled out for the
following reasons: L. reuteri compared with simethicone rather than placebo, use of multiple probiotics,
primary focus was gut microbiota, a different strain of Lactobacillus was used, feces samples were the
observed outcome, and the focus was on safety rather than efficacy. This process is demonstrated in the
PRISMA Flow Diagram seen in Figure 1. The remaining 3 articles were selected for qualitative analysis in
this study.
Table 1. Criteria for Selection of Studies for Analysis
Inclusion Criteria

Exclusion Criteria

Randomized control trials

Different strain of lactobacillus

Predominantly breastfed infants

Solely formula fed infants

L. reuteri as only probiotic strain
Evaluating infant colic
RESULTS
Study 1
Probiotics for Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating
Lactobacillus reuteri DSM 17938. Chau et al.
Objective: Investigated Lactobacillus reuteri DSM 17938 for treating infant colic vs. placebo in Canadian
infants
Study Design
This was a randomized, double-blind, placebo-controlled trial involving 55 infants with colic, as
defined by the modified Wessel criteria. Participants were recruited from The Hospital for Sick Children
and from pediatric practices in Toronto, Ontario, Canada. Table 2 outlines the inclusion and exclusion
criteria. The 55 infants were randomly assigned using a 2-treatment randomization schedule. This
schedule was computer generated by personnel from the Independent Research Support Pharmacy, and
these individuals were not participating in the study.
Participants received L. reuteri or placebo for 21 days with the purpose of assessing reduction in
crying time. The L. reuteri group was given a suspension of freeze-dried L. reuteri DSM 17938 in a
combination of medium-chain triglyceride oil, sunflower oil and silicon dioxide. The concentration of the
probiotic in the oil was 1 x 108 CFU per 5 drops. The placebo had the exact same ingredients, but without
L. reuteri. The primary outcome evaluated the average length of crying times, from baseline (day 0) to the
end of treatment (day 21). The secondary outcome measured the number of participants who responded
to treatment, meaning those infants with reduction in daily average crying times of more than 50% from
baseline, on days 7, 14, and 21. During the duration of the treatment period, parents were instructed to
record any adverse events, weekly weights, bowel changes, and digestive discomfort.
On enrollment day, guardians were interviewed, and the referring pediatrician performed an
examination and recorded infant growth parameters. Caregivers in both groups were told to give 5 drops
orally, at the same time once daily for 21 days and to refrain from “other modes of therapy or methods to

console their infant”.8 The potential modes and methods of consolation were not defined. Parents keep a
maternal diary to record colic episodes, daily crying time, feeding schedule, stool frequency and
characteristics, and any adverse events, including how often and how long each adverse lasted.
Follow-up visits were scheduled for day 7, 14, and 21 by the same referring pediatrician and a
study investigator to monitor infant progress. Colic symptoms, weight, and any adverse events were
reported. On the last day of the study, day 21, the same referring pediatrician performed an examination
and a study investigator collected any extra study product and the diary. The diaries were reviewed
independently by the pediatrician and 2 study team investigators for completion. Data were entered
independently by 2 study investigators, and then reviewed by another investigator to ensure accurate
diary data transfer.
Table 2. Inclusion and Exclusion Criteria for Study 1
Inclusion Criteria

Exclusion Criteria

Diagnosis of infantile colic defined by a modified
definition of Wessel criteria at study
commencement

Major medical problem or acute illness, including
gastroesophageal reflux, as determined by a
pediatrician

Age 3 weeks to 6 months at study
commencement

History of antibiotic treatment before or during study

Exclusively breastfed

History of probiotic or L. reuteri supplementation

Term delivery (≥37 weeks gestation at birth)

Allergies to any of the ingredients in the probiotic

5-minute Apgar score ≥7

Concurrent participation in another clinical trial

Birth weight ≥2500 g
Study Results
A total of fifty-two infants (24 from the L. reuteri group and 28 from the placebo group) completed
the study and their results were analyzed. Using intention-to-treat approach, the total average crying time
in minutes from day 0 to day 21 of treatment was shorter in the L. reuteri group versus the placebo group:
1719 +/- 750 minutes, 2195 +/- 764 minutes, respectively; p = .028. Compared to the placebo group, the
daily average crying times in the L. reuteri group were significantly lower on day 7, 14, and 21. The
average daily crying times at the end of the study were 60 minutes for the L. reuteri group and 102
minutes for the placebo group; p = .045. Additionally, by the end of the study 70.8% of the L. reuteri group
had a ≥50% reduction in their crying times, while only 21.4% of the placebo group had a ≥50% reduction
in their crying times. While the L. reuteri group had more members with ≥50% reduction in their crying
times by day 7 and 14, the differences from the placebo group were not statistically significant. There
were no adverse events reported by any of the participants and there were no growth differences seen
between the two groups.
Study Critique
This study had a lot of strengths. It was a randomized, double-blind, placebo-controlled trial with
inclusion criteria of 3 weeks to 6 months to capture any infants with delayed onset of colic. The placebo
group received the exact same formulation as the study group, minus the live bacteria, and this ensured
blinding was not compromised. In an effort to avoid confounding variables, caregivers of the participants
were explicitly told to not try any other forms of consolation. However, they did not define what they
meant by “other modes of therapy or methods” for consoling their infant. This could have an impact on the

results if parents were instructed to not even hold their infants during times of colic. Another strength of
this study was that parents recorded various aspects of the infants life during the clinical trial, including
feeding schedule, stool frequency and characteristics, and any adverse events experienced.
The pediatrician who performed the original medical examination of the infants on enrollment (day
0) also performed the medical examination at the end of the study on day 21, which allowed for thorough
consistency in evaluation of the infants. The data from the diaries the caregivers filled out were reviewed
independently by the pediatrician and 2 study team investigators, then they were reviewed by a third
investigator to ensure that the data was accurately transferred.
A limitation to this study is that the data relied on accurate recording by the caregiver. The
researchers provided important aspects to be recorded, but there is no way to definitively know that each
caregiver followed through with accurate reporting. There is also no way to know that the parent
administered the 5 oral drops every day and that they were given at the same time each day. Another
limitation was that some of the patients were recruited from The Hospital for Sick Children, but no
clarification was given on what these patients were at the hospital for. While exclusion criteria did omit
any infants with major medical conditions or acute illnesses, if the patients had been admitted for any
reason this could have impacted their response to the treatment.
Study 2
Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial.
Savino et al.
Objective: To test the efficacy of Lactobacillus reuteri in treating infantile colic and to evaluate its
relationship to gut microbiota.
Study Design
This was a randomized, double-blind, placebo-controlled trial, involving 50 exclusively breastfed
infants (29 boys and 21 girls) that had previously been diagnosed with infantile colic according to modified
Wessel’s criteria. The infants were recruited from the Department of Pediatrics at the Regina Margherita
Children Hospital in Turin, Italy and an independent statistician randomly assigned infants using a
computer-generated randomization list. Inclusion and exclusion criteria are listed in Table 3.
Table 3. Inclusion and Exclusion Criteria for Study 2
Inclusion Criteria

Exclusion Criteria

Infants born “at term”

Mother consuming cow’s milk

Adequate for gestational age Chronic illness or gastrointestinal disorders
Aged 2-16 weeks

Intake of probiotics in the week prior to recruitment

Exclusively breastfed

Use of antibiotics in week prior to recruitment
Any formula feeding
Use of acid-blocking medication

The experimental group received a suspension of freeze-dried L. reuteri in sunflower oil and
medium-chain triglyceride oil, with a concentration of 1 x 108 CFU in 5 drops. The placebo group received

the same oil mixture without the L. reuteri. The oils were the same in taste and appearance and both
were provided in identical 5mL dropper bottles. Parents were instructed to keep dropper bottles
refrigerated in between uses. For 21 days, both groups were administered 5 oral drops daily, 30 minutes
before their first feeding of the day. A structured diary was kept by the parents and daily duration of
crying, stool characteristics, and any gastrointestinal disturbances or adverse effects were recorded.
The measured outcomes included a primary outcome of reduction in daily crying time to less than
3 hours by day 21, and a secondary outcome of ≥50% reduction from the baseline duration of daily crying
at days 7, 14, and 21. Infants who had ≥50% reduction in their crying time were referred to as
“responders.” At day 0, the infants were medically examined, and a baseline was set for growth to be
compared with growth at day 21. Patients had follow-up appointments with the same pediatrician on day
7 and day 21.
Study Results
Of the 50 infants enrolled, four were removed from the study by day 7: one due to diagnosis of
gastroesophageal reflux, one due to development of fever, and two for parents’ failure to record in the
diary. All four of these patients were in the placebo group. Statistically significant differences were found
in the daily crying times of the probiotic group versus the placebo group, p = .022. At day 21, the L. reuteri
group was found to have a significant reduction in their daily crying time from baseline, while the placebo
group did not. The probiotic group’s average daily crying times decreased from 370 minutes at baseline to
35 minutes at day 21, while the placebo group’s daily crying times only decreased from 300 at baseline to
90 at day 21. Secondarily, there were significantly more responders in the L. reuteri group versus the
placebo group on days 7 (p = .006), 14 (p = .007), and 21 (p = .036). An intention-to-treat analysis (in
which all 4 of the lost placebo participants were counted as responders) still showed that there were
significantly more responders in the L. reuteri group versus the placebo group.
Study Critique
One of the major strengths of this study is that it was double-blinded, randomized, and placebocontrolled. There were no identifiable differences in the appearance and taste of the L. reuteri oil versus
the placebo oil and this lent further to the blinding of the study. There was an intention to treat analysis
performed, which strengthens the validity of the findings. Another potential strength of this study is that
the infants’ feces were evaluated for colonization with L. reuteri. This confirms adequate L. reuteri
concentrations in the gastrointestinal tract of the experimental group and verifies the consistent
administration of the probiotic.
This study failed to explicitly define the gestational age at birth in the inclusion criteria. The infants
were described as being “born at term.” This is an outdated designation that has been replaced with
“early term” and “late term.” “Term” can refer to anywhere from 37 weeks to 42 weeks.9 This is a
considerable amount of time in the life of a newborn. This is a possible flaw in the study, as gestational
age could have impacts on the study’s findings. A major limitation of this study was that findings were
dependent on the parents accurately reporting daily crying times. While explicit instructions were given to
the parents, there was no way of verifying the accuracy of their reports. The subjectiveness of the
outcomes could potentially impact the validity of the study’s findings.
Study 3
Lactobacillus reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A
Randomized, Double-Blind, Placebo-Controlled Trial. Szajewska et al.
Objective: To determine if the administration of Lactobacillus reuteri is beneficial in the treatment of
breastfed infants with infantile colic.

Study Design
This was a randomized, double-blind, placebo-controlled trial, involving 80 infants under 5 months
old that were exclusively or predominantly breastfed. Infants were recruited from a primary care practice
in Warsaw, Poland and suffering from infantile colic, defined as 3 or more hours of crying per day, 3 or
more days per week, within 7 days of enrollment in the study. Table 4 outlines the inclusion criteria.
Table 4. Inclusion and Exclusion Criteria for Study 3
Inclusion Criteria

Exclusion Criteria

Full-term infants aged <5 months with infantile
coli

Acute or chronic illness

Exclusively or predominantly (>50%) breastfed

Gastrointestinal disorders
Use of antibiotics or probiotics within a week of the
study

Study Results
Only one patient was lost to follow-up, a patient in the probiotic group, due to no diary return and
discontinuation of product administration. The crying times were significantly reduced in the probiotic
group compared with the placebo group at all points throughout the study period. The probiotic group
had significantly more infants with a ≥50% reduction in their crying time when compared to the placebo
group on days 7, 14, 21, and 28. The average crying time of the L. reuteri group was also significantly
lower than the probiotic group throughout the 21-day period. The number needed to treat (NNT) for a
≥50% reduction in crying time was 7 at day 7, and only 2 at days 14 and 21.
Study Critique
This study had many strengths. It was a randomized, double-blind, placebo-controlled trial
conducted with 80 infants with infantile colic <5 months old, so all the infants were of similar age. While
80 test subjects is not a significantly large sample size, it is still considerably larger than the other two
studies, therefore this was considered a strength. Participants were exclusively or predominantly
breastfed, which fit the inclusion criteria for this analysis, however, it would have been preferred if the
participants were exclusively breastfed. As with the other two studies, the placebo was identical in taste
and appearance to the L. reuteri product, and this helped to ensure proper blinding. This study not only
followed up with participants multiple times during the treatment period, but also 7 days after treatment in
an effort to evaluate for residual effects. The same pediatrician who did the patient evaluation at the
beginning of the study did every subsequent evaluation, and this helped prevent any variation in provider
evaluation. This consistency allowed for a better determination of change from baseline for each patient.
Another strength was that all caregivers were given explicit directions or filling out their diary,
including the exact aspects related to colic to record, the time the product was given, quality of family life,
and any adverse events. However, there were no measures taken to assess the compliance of the diary
recording. It was a strength that these diaries were analyzed independently by a study physician and two
other investigators, all of whom were blinded from treatment assignment. As with the other studies, the
use of a diary as the only means of measuring the infants’ colic makes the measurements completely
subjective. This could affect the validity of the findings. A major limitation to this study is that there was no
assessment of compliance of the diary recordings or proper administration of the product. Without
ensuring strict compliance of the participants, the results could be invalid.

DISCUSSION
The primary outcome being investigated in this review was the overall reduction infant crying
time. Each study examined a reduction of crying time ≥50% on day 7, 14 and 21, with the exception of the
study done by Szajewska, et al. that included follow-up day 28. While the studies also looked at overall
reduction in crying-time minutes, this was not a measure that could be evaluated for number needed to
treat (NNT) due to the fact that the minutes were given for the groups as a whole. Therefore, this review
focuses on the findings related to a ≥50% reduction in crying-time. The studies concluded similar results,
insinuating that probiotic use can be implemented as a tool to help with infant colic. Table 5 summarizes
the results of each study.
Table 5. Comparison Chart of Studies
Study 1: Chau, et al.8

Study 2: Savino, et al.10

Study 3: Szajewska, et
al.11

Objective

Investigated Lactobacillus
reuteri DSM 17938 for
treating infant colic vs.
placebo in Canadian infants

To test the efficacy of
Lactobacillus reuteri in
treating infantile colic and
to evaluate its relationship
to gut microbiota

To determine if the
administration of
Lactobacillus reuteri is
beneficial in the treatment
of breastfed infants with
infantile colic

Study Design

Double-blind, Placebo
controlled RCT

Double-blind, Placebo
controlled RCT

Double-blind, Placebo
controlled RCT

Test Number

24

25

40

Control
Number

28

21

40

Probiotic
Treatment

Suspension of freeze-dried
L. reuteri DSM 17938 1x108
per 5 drops in a mixture of
sunflower oil, medium-chain
triglyceride oil, and silicon
dioxide

Suspension of freezedried L. reuteri DSM
17938 1x108 per 5 drops
in a mixture of sunflower
oil & medium-chain
triglyceride oil

Suspension of freeze-dried
L. reuteri DSM 17938
1x108 per 5 drops in a
mixture of sunflower oil &
medium-chain
triglyceride oil with vitamin
D3 added

Placebo
Treatment

Combination of sunflower
oil, medium-chain
triglyceride oil, and silicon
dioxide

Combination of sunflower
oil and medium-chain
triglyceride oil

Combination of sunflower
oil and medium-chain
triglyceride oil, with vitamin
D3 added

Age of
Participants

<5 months

2 - 16 weeks

3 weeks to 6 months

Gestational
Age at
Delivery

≥37 weeks

Term

Full-term

Feeding Type

Exclusively breastfed

Exclusively breastfed

Predominantly breastfed

Follow-up
Period

Day 7, 14, and 21

Day 7, 14, and 21

Day 7, 14, 21, and 28

Conclusion

Infants in the L. reuteri
group experienced a
reduction in crying time
compared to placebo

L. reuteri improves
symptoms of infantile
colic in breastfed infants
with colic

L. reuteri reduces crying
time in predominantly
breast-fed infants with
colic

NNT: Day 7,
14, 21, 28

8, 3, 2, N/A

2, 3, 4, N/A

7, 2, 2, 3

The studies were similar in many aspects, including overall objective, study design, methods,
probiotic type and follow-up period. All three studies focused on reduction in crying time over a 21-day
period of treatment. They each identified colic using the modified Wessel’s criteria, which is defined as
“crying and/or fussing ≥3 hours/day for ≥3 days/week for one week.”9 This is important because the goal of
this research was to determine if L. reuteri was effective in overall reduction of crying-time in infants with
colic. If there was not a consistent definition of colic, this would have significant impacts on the ability to
compare the studies’ results. All three studies were randomized control trials and double-blinded, which
are considered the best tests to judge efficacy. They each used L. reuteri DSM 17938 suspended in a
combination of sunflower oil and medium-chain triglyceride oil. The placebos used in all three studies
were oil mixtures identical to the experimental product in taste and appearance but did not contain L.
reuteri. They all had a similar method for data collection, which involved caregivers recording various
aspects of the infant’s symptoms into a diary. Each study had follow-ups on day 7, 14 and 21, however,
the Szajewska et al. study included a follow-up on day 28, a week after the conclusion of the treatment, to
further assess the effect of the intervention.
While these studies were very similar, they did have aspects that set them apart from one
another. Savino et al. and Chau et al. had a primary outcome of reduction in average crying time and a
secondary outcome of a decrease in daily average crying time of ≥50% from baseline. However, the
Szajewska et al. study had these outcomes reversed; the primary outcome was evaluating a decrease in
daily average crying time of ≥50% from baseline, and the secondary outcome was a reduction of average
crying time. Another difference was that only Chau et al. and Szajewska et al. explicitly identified the
gestational age at delivery. Chau et al. used “infants ≥37 weeks” and Szajewska, et al. used “full term”
infants, which is defined as ≥39 weeks. However, Savino et al. simply identified their subjects as “term”
infants, which is a gestational age at birth of anywhere from 37 weeks to 42 weeks.8 While no obvious
differences were seen in the studies, this discrepancy between the subjects’ gestational age at birth could
potentially impact the results. Savino, et al. was also the only study that told mothers to avoid consuming
cow’s milk during treatment and Szajewska, et al. was the only study that used “predominantly breastfed”
infants as opposed to exclusively breastfed infants. While these differences may not have had dramatic
impact on the outcomes of the studies, it would have been preferable if all three studies had the exact
same requirements.
Each study had their share of strengths and weaknesses. Chau et al. is a randomized, doubleblind, placebo-controlled trial with an age range of up to 5 months old, and an almost equal number of
males to females. However, this study was limited due to its small sample size. Savino et al. was also a
double-blind, placebo-controlled trial, but this study used a smaller age range for study participants, with
only up to 4 months of age. This study had just as small a sample size as Chau et al. Like the other two
studies, Szajewska et al. was a randomized, double-blind, placebo-controlled trial but it had the largest
sample size of all of the studies. Each study had the limitation of having no objective measure to ensure
compliance of probiotic and placebo administration and accurate records. Chau et al. and Szajewska et
al. used the same physician for initial medical examination and the final medical examination, whereas
Savino et al. did not specify. Due to the larger sample size, additional day of participant follow-up, as well
as using full-term infants, it seems that Szajewska et al. may be the most thorough study out of the three.

All three studies provide evidence that the use of probiotics, specifically L. reuteri, can be used as
a treatment method for infant colic. Duration of crying time in the L. reuteri groups was significantly
reduced on day 21 in every study. Chau et al. found that when compared to placebo, the L. reuteri group
had a significantly greater reduction in average crying time at days 7, 14, and 21, but only a significantly
higher number of responders by day 21. Savino et al. found that when compared to placebo, the L.
reuteri group only had a significantly greater reduction in average crying by day 21, but had a significantly
greater number of responders on days 7, 14 and 21. Szajewska et al. had a statistically significant
reduction in average crying times and reduction in crying time ≥50% from day 7 to day 21. A reduction in
crying time of ≥50% was measured in all studies, and from this data NNT was calculated for each study
(as seen in Table 5).
Some limitations of this systematic review were that these studies were very similar, and
subsequently the studies often referenced one another. It is possible that they were modeled after one
another, and while this is not a flaw, it may have been more informative to have additional studies
referenced that were not already a part of this analysis. Also, none of the studies had an impressive
sample size or used a measure other than subjective recording of symptoms by the parents. The small
sample sizes are understandable considering that it is notoriously difficult to recruit large numbers of
infants for RCTs, but nonetheless, larger sample sizes would have provided more weight to the findings
of the studies. Further studies need a more direct way of making sure infants are all receiving the correct
dosage and parents are recording symptoms accurately.
CONCLUSION
The findings of these three studies substantiate the claim that L. reuteri is significantly more
effective than placebo in reducing crying-time in infants with colic. There were also no findings to suggest
that giving an L. reuteri supplement would have any adverse effects on an infant. Therefore, this analysis
supports the use of L. reuteri in the treatment of breastfed infants with colic. Unfortunately, the findings of
this analysis can only truly be applied to breastfed infants and it will be necessary for further studies to
address formula-fed infants. These future studies should control the supplied formula, as many formulas
already contain probiotics, and this could confound the results. It could be beneficial to explore other
supplied forms of L. reuteri, for instance, having solely formula-fed infants randomly assigned to either
formula that has been fortified with L. reuteri, or an identical placebo formula without any probiotic.
Improvements should be made to future studies regarding sample size, and verification of diary
tracking and product administration. Despite the well-known difficulty in accomplishing large RCTs with
infants, larger sample sizes should be completed. A possible method of verifying diary compliance would
be to make the diary submissions online, with daily or weekly submission requirements. More studies
should employ fecal testing, as this could further verify product administration and ensure proper L.
reuteri concentrations in the test subjects.
It also may be valuable to have studies focus solely on early-term or preterm infants so that
analyses can be completed on this population independent of full-term infants. Lastly, there has been
intriguing exploration into the value of giving L. reuteri prophylactically. While preliminary findings have
been positive and suggest that L. reuteri supplementation could prevent the development of colic,12,13
more studies are needed in this area in order to draw any conclusions. In the meantime, based on the
findings of these three studies, our recommendation is that breastfed infants with established colic should
be treated promptly with L. reuteri.
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